말초신경자극기 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 적응증별, 작용기전별, 최종사용자별, 국가별 및 부문별 예측(2026-2033년)

Peripheral Nerve Stimulators Market Summary

The Peripheral Nerve Stimulators Market size was valued at USD 299.3 million in 2025 and is projected to grow from USD 351.8 million in 2026 to USD 898.1 million by 2033, at a CAGR of 14.3% from 2026 to 2033. U.S. dominated the market, accounting for the largest revenue share of 93.6%. The rising prevalence of peripheral neuropathy is a key driver of the peripheral nerve stimulator market.

Peripheral nerve stimulation delivers electrical impulses to or around specific peripheral nerves to modulate pain signals while avoiding direct stimulation of the spinal cord. The market includes implantable, percutaneous, and temporary peripheral nerve stimulation systems, with applications spanning peripheral neuropathic pain, postoperative pain, musculoskeletal pain, post-amputation pain, chronic back and lower-extremity pain, and selected headache and pelvic pain conditions. Technological advancements in lead design, stimulation programming, ultrasound-guided implantation, wearable components, and temporary stimulation systems have expanded the applicability of PNS and improved procedural flexibility.

Peripheral neuropathy is becoming common due to the growing incidence of diabetes, an aging population, obesity, chronic kidney disease, autoimmune disorders, cancer therapies, and other metabolic and neurological conditions that damage peripheral nerves. Diabetic peripheral neuropathy remains the most prevalent form of the disease. It is recognized as a major long-term complication of diabetes, while chemotherapy-induced peripheral neuropathy is also emerging as a significant clinical concern with the expanding use of cancer treatments. As the number of individuals experiencing chronic neuropathic pain, numbness, tingling, and sensory dysfunction continues to rise, there is a growing need for effective long-term pain management solutions beyond conventional pharmacological therapies. This increasing disease burden is accelerating the adoption of peripheral nerve stimulators, which offer a targeted, minimally invasive approach to managing chronic neuropathic pain and improving patients' quality of life.

According to a study published on ScienceDirect in April 2025, a comprehensive search of four English and three Chinese databases identified observational studies on the prevalence of Painful Diabetes-related Peripheral Neuropathy (PDPN) published through June 22, 2024. Based on the 41 studies included in the analysis, the pooled global prevalence of PDPN was 46.7%.

The rising prevalence of musculoskeletal conditions is contributing to the growing demand for peripheral nerve stimulators, as an increasing number of patients experience chronic pain and functional limitations associated with these disorders. Conditions such as osteoarthritis, chronic back pain, joint-related disorders, and sports-related injuries are becoming more common due to factors including population aging, increasing obesity rates, and rising physical activity-related injuries. The growing patient burden associated with these musculoskeletal conditions has increased the number of individuals requiring long-term pain management solutions. As the prevalence of these conditions continues to rise, demand for targeted therapies, such as peripheral nerve stimulation, is increasing to address persistent pain and improve patient mobility.

Peripheral Nerve Stimulators Market Report Segmentation

This report forecasts revenue growth at the global and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Peripheral Nerve Stimulators Market report based on type, indication, mechanism, end user, and country:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Temporary Percutaneous Systems
• Wireless Micro-Implantable Systems
• Traditional IPG Systems
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Restorative Multifidus Stimulation
• Peripheral Neuropathic & Post-Surgical/Traumatic Pain
• Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
• External Direct Power
• Transcutaneous Wireless Power
• Internal Battery Power
• End User Outlook (Revenue, USD Million, 2021-2033)
• Hospital Outpatient Departments
• Ambulatory Surgical Centers
• Outpatient Interventional Pain Clinics / OBLs
• Country Outlook (Revenue, USD Million, 2021-2033)
• U.S.
• Canada
• Germany
• Australia
• UK
• Italy
• Spain
• Denmark
• Rest of the World (France, Japan, Lebanon, Israel)

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Indication
  • 1.1.3. Mechanism
  • 1.1.4. End-User
  • 1.1.5. Country scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Peripheral Nerve Stimulators Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic pain disorders
    • 3.2.1.2. Growing preference for minimally invasive therapies
    • 3.2.1.3. Opioid crisis and shift toward non-opioid pain management
    • 3.2.1.4. Expanding applications beyond chronic pain
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of devices and procedures
    • 3.2.2.2. Risk of complications and device-related issues
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Expansion into new indications
    • 3.2.3.2. Adoption in outpatient & home-care settings
    • 3.2.3.3. Rising demand for personalized pain management
    • 3.2.3.4. Integration of Wireless and Wearable Technologies
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Competition from alternative therapies
    • 3.2.4.2. Patient selection challenges
• 3.3. Peripheral Nerve Stimulators Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Peripheral Nerve Stimulators Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Peripheral Nerve Stimulators Market Type Movement Analysis
• 4.3. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Temporary Percutaneous Systems
  • 4.4.1. Temporary percutaneous systems market estimates and forecasts for 2021 to 2033 (USD Million)
• 4.5. Wireless Micro-Implantable Systems
  • 4.5.1. Wireless micro-implantable systems market estimates and forecasts for 2021 to 2033, (USD Million)
• 4.6. Traditional IPG Systems
  • 4.6.1. Traditional IPG systems market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 5. Peripheral Nerve Stimulators Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Peripheral Nerve Stimulators Market Indication Movement Analysis
• 5.3. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 5.4. Restorative Multifidus Stimulation
  • 5.4.1. Restorative multifidus stimulation market estimates and forecasts for 2021 to 2033, (USD Million)
• 5.5. Peripheral Neuropathic & Post-Surgical/Traumatic Pain
  • 5.5.1. Peripheral neuropathic & post-surgical/traumatic pain market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Peripheral Nerve Stimulators Market: Mechanism Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Peripheral Nerve Stimulators MarketPeripheral Nerve Stimulators Market Mechanism Movement Analysis
• 6.3. Peripheral Nerve Stimulators MarketPeripheral Nerve Stimulators Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
• 6.4. External Direct Power
  • 6.4.1. External direct power market estimates and forecasts for 2021 to 2033, (USD Million)
• 6.5. Transcutaneous Wireless Power
  • 6.5.1. Transcutaneous wireless power market estimates and forecasts for 2021 to 2033, (USD Million)
• 6.6. Internal Battery Power
  • 6.6.1. Internal battery power market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 7. Peripheral Nerve Stimulators Market: End-User Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Peripheral Nerve Stimulators Market End-User Movement Analysis
• 7.3. Peripheral Nerve Stimulators Market Size & Trend Analysis, by End-User, 2021 to 2033 (USD Million)
• 7.4. Hospital Outpatient Departments
  • 7.4.1. Hospital outpatient departments market estimates and forecasts for 2021 to 2033, (USD Million)
• 7.5. Ambulatory Surgical Centers
  • 7.5.1. Ambulatory surgical centers market estimates and forecasts for 2021 to 2033 (USD Million)
• 7.6. Outpatient Interventional Pain Clinics / OBLs
  • 7.6.1. Outpatient interventional pain clinics / OBLs market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 8. Peripheral Nerve Stimulators Market: Country Estimates & Trend Analysis

• 8.1. Country Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. U.S.
  • 8.3.1. Key country dynamics
  • 8.3.2. Competitive scenario
  • 8.3.3. Regulatory framework
  • 8.3.4. Reimbursement scenario
  • 8.3.5. U.S. market estimates and forecasts, 2021 - 2033
• 8.4. Canada
  • 8.4.1. Key country dynamics
  • 8.4.2. Competitive scenario
  • 8.4.3. Regulatory framework
  • 8.4.4. Reimbursement scenario
  • 8.4.5. Canada market estimates and forecasts, 2021 - 2033
• 8.5. Germany
  • 8.5.1. Key country dynamics
  • 8.5.2. Competitive scenario
  • 8.5.3. Regulatory framework
  • 8.5.4. Reimbursement scenario
  • 8.5.5. Germany market estimates and forecasts, 2021 - 2033
• 8.6. UK
  • 8.6.1. Key country dynamics
  • 8.6.2. Competitive scenario
  • 8.6.3. Regulatory framework
  • 8.6.4. Reimbursement scenario
  • 8.6.5. UK market estimates and forecasts, 2021 - 2033
• 8.7. Italy
  • 8.7.1. Key country dynamics
  • 8.7.2. Competitive scenario
  • 8.7.3. Regulatory framework
  • 8.7.4. Reimbursement scenario
  • 8.7.5. Italy market estimates and forecasts, 2021 - 2033
• 8.8. Spain
  • 8.8.1. Key country dynamics
  • 8.8.2. Competitive scenario
  • 8.8.3. Regulatory framework
  • 8.8.4. Reimbursement scenario
  • 8.8.5. Spain market estimates and forecasts, 2021 - 2033
• 8.9. Denmark
  • 8.9.1. Key country dynamics
  • 8.9.2. Competitive scenario
  • 8.9.3. Regulatory framework
  • 8.9.4. Reimbursement scenario
  • 8.9.5. Denmark market estimates and forecasts, 2021 - 2033
• 8.10. Australia
  • 8.10.1. Key country dynamics
  • 8.10.2. Competitive scenario
  • 8.10.3. Regulatory framework
  • 8.10.4. Reimbursement scenario
  • 8.10.5. Australia market estimates and forecasts, 2021 - 2033
• 8.11. Rest of the World (France, Japan, Lebanon, Israel)
  • 8.11.1. Key country dynamics
  • 8.11.2. Competitive scenario
  • 8.11.3. Regulatory framework
  • 8.11.4. Reimbursement scenario
  • 8.11.5. Rest of the World (France, Japan, Lebanon, Israel) market estimates and forecasts, 2021 - 2033

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
  • 9.2.1. Innovators
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Global Key company market share analysis, 2024
  • 9.3.4. Boston Scientific Corporation (Nalu Medical)
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product Type benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Medtronic plc (SPR Therapeutics)
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product Type benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Curonix LLC (Stimwave Technologies)
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product Type benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Neuspera Medical, Inc
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product Type benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Bioventus Inc. (StimRouter)
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product Type benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. NEURIMPULSE s.r.l.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product Type benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Nervonik
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product Type benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Neuros Medical
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product Type benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Mainstay Medical
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product Type benchmarking
    • 9.3.12.4. Strategic initiatives
• 9.4. Heat Map Analysis/ Company Market Position Analysis
• 9.5. Estimated Company Market Share Analysis, 2024
• 9.6. List of Other Key Market Players